stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) Gross margin
Krystal Biotech, Inc.'s gross margin over the twelve months to 30 September 2026 was 94.3%, up 0.2 percentage points from fiscal 2025 (94.1%). Over the past ten years it has ranged from 0.00% (fiscal 2022) to 94.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 94.1% | 0.99 |
| FY2024 | 93.1% | (0.81) |
| FY2023 | 93.9% | 93.90 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 94.1% | (0.53) |
| Jun 2026 | 94.6% | 0.03 |
| Mar 2026 | 94.6% | 0.73 |
| Dec 2025 | 93.8% | (1.80) |
| 25 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 100.0% |
| SYRE Spyre Therapeutics, Inc. compare | 100.0% |
| IBRX ImmunityBio, Inc. compare | 99.3% |
| KRYS Krystal Biotech, Inc. | 94.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 91.0% |
| TGTX TG Therapeutics, Inc. compare | 82.4% |
| TWST Twist Bioscience Corporation compare | 52.0% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on KRYS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement